Seasonal influenza vaccination of healthy working-age adults

A review of economic evaluations

Justin Gatwood, Martin I. Meltzer, Mark Messonnier, Ismael R. Ortega-Sanchez, Rajesh Balkrishnan, Lisa A. Prosser

Research output: Contribution to journalReview article

20 Citations (Scopus)

Abstract

The recent impact of influenza on the working-age population of the US has led to changes in the recommendations for vaccination against seasonal influenza; however, the implications of vaccinating such a population have been debated. A review of cost-effectiveness analyses of vaccinating the working-age population of the US against seasonal influenza was conducted using articles published between January 1990 and January 2010. Studies considered for inclusion were identified using MEDLINE, EMBASE and Econlit. Reviewers worked in pairs, and each team member independently extracted relevant data using a standard abstraction form. The source and appropriateness of parameters (epidemiological data, probabilities and costs), the designs employed and the sufficiency of sensitivity analysis were considered during review. Key inputs extracted from the selected studies included influenza or influenza-like illness attack rates, outpatient visits averted, total vaccination days and lost workdays.Seven studies were identified as appropriate for this review. All studies were conducted in the US and from the societal perspective; three were randomized controlled trials and the remaining four were economic simulation models comparing vaccination and influenza antiviral drugs or no intervention; analyses focused on healthy working-age adults aged 1849 years. Results ranged from net savings of $US68.96 to net costs of $US85.92 per person vaccinated (four studies) and net costs of $US1041005 per episode of influenza averted (one study). Only two studies reported cost-effectiveness ratios; these ranged from $US26565 to $US50512 per quality-adjusted life-year gained. Nearly all of the studies conducted sensitivity analysis; results were most sensitive to variation in wage rates, levels of worker productivity, the costs and effectiveness of vaccination, and the rate of influenza illness. Review of the included studies suggests that seasonal influenza vaccination of healthy, working-age adults is generally not cost saving, requiring an investment to generate health benefits. The decision to vaccinate such a group will depend upon the societal and payer valuation of those benefits.

Original languageEnglish (US)
Pages (from-to)35-48
Number of pages14
JournalDrugs
Volume72
Issue number1
DOIs
StatePublished - Jan 1 2012
Externally publishedYes

Fingerprint

Human Influenza
Cost-Benefit Analysis
Vaccination
Costs and Cost Analysis
Population
Economic Models
Quality-Adjusted Life Years
Salaries and Fringe Benefits
Insurance Benefits
MEDLINE
Antiviral Agents
Outpatients
Randomized Controlled Trials

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)

Cite this

Gatwood, J., Meltzer, M. I., Messonnier, M., Ortega-Sanchez, I. R., Balkrishnan, R., & Prosser, L. A. (2012). Seasonal influenza vaccination of healthy working-age adults: A review of economic evaluations. Drugs, 72(1), 35-48. https://doi.org/10.2165/11597310-000000000-00000

Seasonal influenza vaccination of healthy working-age adults : A review of economic evaluations. / Gatwood, Justin; Meltzer, Martin I.; Messonnier, Mark; Ortega-Sanchez, Ismael R.; Balkrishnan, Rajesh; Prosser, Lisa A.

In: Drugs, Vol. 72, No. 1, 01.01.2012, p. 35-48.

Research output: Contribution to journalReview article

Gatwood, J, Meltzer, MI, Messonnier, M, Ortega-Sanchez, IR, Balkrishnan, R & Prosser, LA 2012, 'Seasonal influenza vaccination of healthy working-age adults: A review of economic evaluations', Drugs, vol. 72, no. 1, pp. 35-48. https://doi.org/10.2165/11597310-000000000-00000
Gatwood, Justin ; Meltzer, Martin I. ; Messonnier, Mark ; Ortega-Sanchez, Ismael R. ; Balkrishnan, Rajesh ; Prosser, Lisa A. / Seasonal influenza vaccination of healthy working-age adults : A review of economic evaluations. In: Drugs. 2012 ; Vol. 72, No. 1. pp. 35-48.
@article{d7eb00e049e84d07acf00a502ca61366,
title = "Seasonal influenza vaccination of healthy working-age adults: A review of economic evaluations",
abstract = "The recent impact of influenza on the working-age population of the US has led to changes in the recommendations for vaccination against seasonal influenza; however, the implications of vaccinating such a population have been debated. A review of cost-effectiveness analyses of vaccinating the working-age population of the US against seasonal influenza was conducted using articles published between January 1990 and January 2010. Studies considered for inclusion were identified using MEDLINE, EMBASE and Econlit. Reviewers worked in pairs, and each team member independently extracted relevant data using a standard abstraction form. The source and appropriateness of parameters (epidemiological data, probabilities and costs), the designs employed and the sufficiency of sensitivity analysis were considered during review. Key inputs extracted from the selected studies included influenza or influenza-like illness attack rates, outpatient visits averted, total vaccination days and lost workdays.Seven studies were identified as appropriate for this review. All studies were conducted in the US and from the societal perspective; three were randomized controlled trials and the remaining four were economic simulation models comparing vaccination and influenza antiviral drugs or no intervention; analyses focused on healthy working-age adults aged 1849 years. Results ranged from net savings of $US68.96 to net costs of $US85.92 per person vaccinated (four studies) and net costs of $US1041005 per episode of influenza averted (one study). Only two studies reported cost-effectiveness ratios; these ranged from $US26565 to $US50512 per quality-adjusted life-year gained. Nearly all of the studies conducted sensitivity analysis; results were most sensitive to variation in wage rates, levels of worker productivity, the costs and effectiveness of vaccination, and the rate of influenza illness. Review of the included studies suggests that seasonal influenza vaccination of healthy, working-age adults is generally not cost saving, requiring an investment to generate health benefits. The decision to vaccinate such a group will depend upon the societal and payer valuation of those benefits.",
author = "Justin Gatwood and Meltzer, {Martin I.} and Mark Messonnier and Ortega-Sanchez, {Ismael R.} and Rajesh Balkrishnan and Prosser, {Lisa A.}",
year = "2012",
month = "1",
day = "1",
doi = "10.2165/11597310-000000000-00000",
language = "English (US)",
volume = "72",
pages = "35--48",
journal = "Drugs",
issn = "0012-6667",
publisher = "Adis International Ltd",
number = "1",

}

TY - JOUR

T1 - Seasonal influenza vaccination of healthy working-age adults

T2 - A review of economic evaluations

AU - Gatwood, Justin

AU - Meltzer, Martin I.

AU - Messonnier, Mark

AU - Ortega-Sanchez, Ismael R.

AU - Balkrishnan, Rajesh

AU - Prosser, Lisa A.

PY - 2012/1/1

Y1 - 2012/1/1

N2 - The recent impact of influenza on the working-age population of the US has led to changes in the recommendations for vaccination against seasonal influenza; however, the implications of vaccinating such a population have been debated. A review of cost-effectiveness analyses of vaccinating the working-age population of the US against seasonal influenza was conducted using articles published between January 1990 and January 2010. Studies considered for inclusion were identified using MEDLINE, EMBASE and Econlit. Reviewers worked in pairs, and each team member independently extracted relevant data using a standard abstraction form. The source and appropriateness of parameters (epidemiological data, probabilities and costs), the designs employed and the sufficiency of sensitivity analysis were considered during review. Key inputs extracted from the selected studies included influenza or influenza-like illness attack rates, outpatient visits averted, total vaccination days and lost workdays.Seven studies were identified as appropriate for this review. All studies were conducted in the US and from the societal perspective; three were randomized controlled trials and the remaining four were economic simulation models comparing vaccination and influenza antiviral drugs or no intervention; analyses focused on healthy working-age adults aged 1849 years. Results ranged from net savings of $US68.96 to net costs of $US85.92 per person vaccinated (four studies) and net costs of $US1041005 per episode of influenza averted (one study). Only two studies reported cost-effectiveness ratios; these ranged from $US26565 to $US50512 per quality-adjusted life-year gained. Nearly all of the studies conducted sensitivity analysis; results were most sensitive to variation in wage rates, levels of worker productivity, the costs and effectiveness of vaccination, and the rate of influenza illness. Review of the included studies suggests that seasonal influenza vaccination of healthy, working-age adults is generally not cost saving, requiring an investment to generate health benefits. The decision to vaccinate such a group will depend upon the societal and payer valuation of those benefits.

AB - The recent impact of influenza on the working-age population of the US has led to changes in the recommendations for vaccination against seasonal influenza; however, the implications of vaccinating such a population have been debated. A review of cost-effectiveness analyses of vaccinating the working-age population of the US against seasonal influenza was conducted using articles published between January 1990 and January 2010. Studies considered for inclusion were identified using MEDLINE, EMBASE and Econlit. Reviewers worked in pairs, and each team member independently extracted relevant data using a standard abstraction form. The source and appropriateness of parameters (epidemiological data, probabilities and costs), the designs employed and the sufficiency of sensitivity analysis were considered during review. Key inputs extracted from the selected studies included influenza or influenza-like illness attack rates, outpatient visits averted, total vaccination days and lost workdays.Seven studies were identified as appropriate for this review. All studies were conducted in the US and from the societal perspective; three were randomized controlled trials and the remaining four were economic simulation models comparing vaccination and influenza antiviral drugs or no intervention; analyses focused on healthy working-age adults aged 1849 years. Results ranged from net savings of $US68.96 to net costs of $US85.92 per person vaccinated (four studies) and net costs of $US1041005 per episode of influenza averted (one study). Only two studies reported cost-effectiveness ratios; these ranged from $US26565 to $US50512 per quality-adjusted life-year gained. Nearly all of the studies conducted sensitivity analysis; results were most sensitive to variation in wage rates, levels of worker productivity, the costs and effectiveness of vaccination, and the rate of influenza illness. Review of the included studies suggests that seasonal influenza vaccination of healthy, working-age adults is generally not cost saving, requiring an investment to generate health benefits. The decision to vaccinate such a group will depend upon the societal and payer valuation of those benefits.

UR - http://www.scopus.com/inward/record.url?scp=84055190611&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84055190611&partnerID=8YFLogxK

U2 - 10.2165/11597310-000000000-00000

DO - 10.2165/11597310-000000000-00000

M3 - Review article

VL - 72

SP - 35

EP - 48

JO - Drugs

JF - Drugs

SN - 0012-6667

IS - 1

ER -